PET scans shed light on Drug's effect in Crohn's gut
NCT ID NCT06432764
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small, early-stage study tested whether a new drug called AZD7798 changes how a special imaging tracer binds to the gut in people with Crohn's disease. Nine adults with active Crohn's disease involving the small intestine received multiple doses of AZD7798 and underwent PET scans before and after treatment. The goal was to measure inflammation-related changes in the gut, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD7798
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Stockholm, 14186, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?